Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S).

Nature chemical biology - 1 Nov 2022

Zhang Ziyang, Guiley Keelan Z, Shokat Kevan M

Abstract excerpt

Drugs that directly impede the function of driver oncogenes offer exceptional efficacy and a therapeutic window. The recently approved mutant selective small-molecule cysteine-reactive covalent inhibitor of the G12C mutant of K-Ras, sotorasib, provides a case in point. KRAS is the most frequently mutated proto-oncogene in human cancer, yet despite success targeting the G12C allele, targeted therapy for other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acylation
Share to Cysteine
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oncogenes

Share to Proto-Oncogene Proteins p21(ras)

Share to Serine

Source

Open in PubMed Open full text

Identifiers

PMID: 35864332
DOI: 10.1038/s41589-022-01065-9
PMCID: PMC9596369

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S).PMID 35864332Read ↗

Targeting KRAS G12C with Covalent InhibitorsSemantic proximity Read ↗

Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.Semantic proximity Read ↗

Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D.Semantic proximity Read ↗

Strain-release alkylation of Asp12 enables mutant selective GTP-state targeting of K-Ras(G12D)Semantic proximity Read ↗

Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors.Semantic proximity Read ↗

Targeting cancer with small-molecule pan-KRAS degraders.Semantic proximity Read ↗

Chemoselective Covalent Modification of K-Ras(G12R) with a Small Molecule Electrophile.Semantic proximity Read ↗

Distal Covalent Targeting Suppresses Signaling of Oncogenic K-Ras(G13C) in Cancer Cells.Semantic proximity Read ↗

Beyond KRAS(G12C): Biochemical and Computational Characterization of Sotorasib and Adagrasib Binding Specificity and the Critical Role of H95 and Y96.Semantic proximity Read ↗

The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors.Semantic proximity Read ↗

Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy.Semantic proximity Read ↗

Simultaneous Covalent Modification of K-Ras(G12D) and K-Ras(G12C) with Tunable Oxirane Electrophiles.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.